Officials at Inscripta say they successfully completed scale-up runs and are moving into commercial manufacturing of an anti-aging skincare ingredient.
Commercial biomanufacturing addresses serious challenges in sourcing plant-based ingredients, according to a company spokesperson, including the environmental footprint associated with current extractive sourcing and the limited depth and consistency of supply chains, which can negatively impact availability and affordability. Biomanufacturing also eliminates sensitizing impurities native to plant-based extracts, notes the spokesperson.
Inscripta reportedly is engaged with commercial partners to deliver “an ingredient product with demonstrated efficacy, superior quality, and consistency that will benefit branded manufacturers and their customers.”
“There is an incredible opportunity for the bioeconomy to meet global consumer demands, not just in personal care, but well beyond by improving sustainability, stabilizing supply chains, and reducing time to market,” said Sri Kosaraju, president and CEO, Inscripta. “We not only develop robust and productive strains, but we also create scalable manufacturing supply chains that deliver sought-after materials to market.”
Inscripta’s development program leveraged its GenoScaler™ technology, a novel and proprietary ultra-high-throughput, CRISPR-enabled platform designed to rapidly optimize microbial strains for biomanufacturing, explained Kosaraju, and pointed out that this two-year effort yielded engineered strains with commercially relevant productivities and consistent performance across four orders of magnitude in bioreactor scale.
